SMCR8 Inhibitors
SMCR8 inhibitors encompass a diverse range of chemicals that directly or indirectly modulate the cellular abundance and activities of SMCR8. Bafilomycin A1, a lysosomal proton pump inhibitor, disrupts the acidic environment within lysosomes, impacting autophagy and SMCR8 degradation. Wortmannin, a PI3K inhibitor, indirectly influences SMCR8 by disrupting the PI3K-AKT-mTOR pathway, altering downstream cellular events. Spautin-1 accelerates SMCR8 degradation by inhibiting deubiquitinases, USP10 and USP13. 3-Methyladenine, a PI3KC3/VPS34 inhibitor, disrupts autophagy, influencing SMCR8 turnover.
Chloroquine impairs lysosomal function and autophagy, hindering SMCR8 degradation. Torin1 targets mTOR, indirectly impacting SMCR8 through the modulation of downstream signaling pathways. SB203580, a p38 MAP kinase inhibitor, indirectly influences SMCR8 by disrupting MAPK signaling cascades. MG-132, a proteasome inhibitor, stabilizes ubiquitinated SMCR8, preventing its degradation. CCI-779 (Temsirolimus), an mTOR inhibitor, modulates SMCR8 indirectly by affecting mTOR-associated pathways. U0126, a MEK1/2 inhibitor, disrupts the MAPK/ERK pathway, indirectly influencing SMCR8. These chemicals, through their specific mechanisms, provide valuable tools for dissecting the intricate regulatory networks involving SMCR8 in cellular processes and contribute to a deeper understanding of its functions.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $96.00 $250.00 $750.00 $1428.00 | 280 | |
Bafilomycin A1 inhibits SMCR8 by targeting the lysosomal proton pump. It disrupts the acidic environment within lysosomes, impacting autophagy and the degradation of SMCR8-containing complexes. This leads to the accumulation of SMCR8, hindering its normal cellular functions. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin acts as a potent inhibitor of phosphoinositide 3-kinases (PI3K), affecting the PI3K-AKT-mTOR pathway. By disrupting this pathway, Wortmannin indirectly modulates SMCR8. The inhibition of PI3K signaling cascades alters the downstream cellular events involving SMCR8, impeding its normal activities. | ||||||
Spautin-1 | 1262888-28-7 | sc-507306 | 10 mg | $165.00 | ||
Spautin-1 promotes SMCR8 degradation by inhibiting the activity of USP10 and USP13, deubiquitinases that stabilize SMCR8. By preventing SMCR8 deubiquitination, Spautin-1 accelerates its degradation through the ubiquitin-proteasome system, leading to reduced SMCR8 levels and impaired cellular functions. | ||||||
Autophagy Inhibitor, 3-MA | 5142-23-4 | sc-205596 sc-205596A | 50 mg 500 mg | $56.00 $256.00 | 113 | |
3-Methyladenine disrupts autophagy by inhibiting class III phosphoinositide 3-kinases (PI3KC3/VPS34). This disturbance in autophagic processes influences the turnover of SMCR8, affecting its cellular abundance and function. The inhibition of autophagy serves as an indirect mechanism for modulating SMCR8 levels and activities. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $68.00 | 2 | |
Chloroquine disrupts lysosomal function and autophagy, affecting the degradation of SMCR8. By inhibiting lysosomal acidification, Chloroquine impairs the fusion of autophagosomes with lysosomes, leading to the accumulation of SMCR8-containing complexes and hindering its normal cellular functions. | ||||||
Torin 1 | 1222998-36-8 | sc-396760 | 10 mg | $240.00 | 7 | |
Torin1 inhibits mTOR, a key regulator of cellular processes. By targeting mTOR, Torin1 indirectly influences SMCR8, as mTOR is involved in pathways intersecting with SMCR8 functions. Inhibition of mTOR alters the cellular landscape, leading to modulation of SMCR8 activities and impacting its normal functions. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAP kinase, affecting MAPK signaling cascades. By disrupting p38 MAP kinase activity, SB203580 indirectly influences SMCR8, as MAPK pathways intersect with cellular processes involving SMCR8. The modulation of MAPK signaling alters the cellular context, leading to changes in SMCR8 functions. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG-132 inhibits the proteasome, impacting the degradation of ubiquitinated proteins, including SMCR8. By blocking the proteasome, MG-132 stabilizes ubiquitinated SMCR8, preventing its degradation. This leads to the accumulation of SMCR8, influencing its cellular functions and dynamics. | ||||||